Compound Tengligen preparation on CT26 tumor growth in mice and in vivo expression of VEGF

Objective To establish Balb/c mice CT26 plantation model, and to investigate the inhibition effect of compound Tengligen preparation on tumor and its influence on vascular endothelial growth factor(VEGF) expression. Methods One hundred seven-week-old male and female Balb/cmice were randomly divided into five groups, namely the control group, tumor-bearing control group, low dose group, medium dose group and high dose group. Each group was inoculated subcutaneously modeling. Two days after modeling, gavage for three weeks in a row was given. Concentration of 0.5g/ml, 1g/ml and 2g/ml of compound Tengligen preparations were administered; and blank control group, tumor-bearing control group were given with saline every day. All mice were sacrificed on the twentysecond day. The tumor weight and inhibition rate were compared, and VEGF expressions were detected by immunohistochemistry. Results Tumor weight and inhibition rate in medium and high dose groups were significantly different with those of low-dose group and the tumor-bearing group( 0.05). VEGF expressions showed significant different among medium and high dose groups and tumor-bearing group( 0.05). Conclusions Compound Tengligen preparation can inhibit tumor growth, lowered the CT26 tumor expression of VEGF, and have anti-angiogenic effect.